Malignant Solid Tumor Clinical Trial
Official title:
A Phase I Study to Assess the Safety and Tolerability of ex Vivo Next-generation Neoantigen-selected Tumor-infiltrating Lymphocyte (TIL) Therapy in Advanced Epithelial Tumors and Immune Checkpoint Blockade (ICB) Resistant Solid Tumors
Background: The presence of T-lymphocytes in resected tumor samples derived from long-term survival patients and the fact that reinvigoration of their functionality through the administration of specific immune-therapies can lead to remarkable antitumor responses supports that lymphocytes play a critical role in cancer immunity. Adoptive cell therapy using tumor-infiltrating lymphocytes product (TIL-ACT) is a well-established combination therapy currently under study in several world reference centers, using an autologous cell product without genetic modifications. This cell product consists of tumor-infiltrating lymphocytes (TIL), which are collected from the patient and expanded in the lab under specific conditions to enhance its antitumoral efficacy before reinfusion in the same patient. However, this cell product alone does not achieve adequate efficacy, and a combination of both previous non-myeloablative lymphodepleting (NMA-LD) chemotherapy and subsequent cytokine therapy (specifically IL-2) is needed to support the expansion of the infused cells. The investigators hypothesize that TILs enriched for neoantigen recognition are superior to unselected TILs at mediating tumor regression in patients with epithelial tumors and even other solid tumors where immune checkpoint blockade (ICB) is approved and used as part of standard therapy. The investigators propose to manufacture a T-cell product composed of TILs that are selected based on their ability to recognize patient-specific neoantigens and to use these to treat patients with metastatic, refractory, epithelial cancers, as well as ICB-resistant solid tumors. Furthermore, it also proposed to study the tumor and T cells at baseline and after treatment to investigate whether specific phenotypic and functional traits may be associated with clinical outcome. Primary objective: To evaluate the safety and the tolerability of ex vivo next generation neoantigen-selected Tumor-infiltrating Lymphocyte (TIL) in patients with metastatic or unresectable epithelial tumors and immune checkpoint blockade (ICB) resistant solid tumors. Secondary objectives: - To determine the success in producing active specific TILs from our target patients. - To evaluate the initial clinical activity of the NEXTGEN-TIL products in our target patients.
Methods: This study is a first-in-human, open-label, non-controlled, single-centre, phase I trial to assess the safety and tolerability of NEXTGEN-TIL-ACT. Given the exploratory nature of the study, there is no formal hypothesis testing and no formal sample size calculation was carried out. A sample size of 10 patients has been selected to provide information about the frequency of treatment-limiting toxicity (TLT). Study treatment: The main study therapy is the Tumor-infiltrating Lymphocyte (NEXTGEN-TIL) product, which is preceded by a preparative non-myeloablative lymphodepleting (NMA-DL) regimen and followed by IL-2 infusion. NEXTGEN-TIL product is a cellular investigational product comprising a live cell suspension of autologous tumor-infiltrating lymphocytes derived from the patient's own tumor. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT01846429 -
Oral Bicarbonate as Adjuvant for Pain Reduction in Patients With Tumor Related Pain
|
Phase 1 | |
| Completed |
NCT01359982 -
Safety and Pharmacokinetic Study of RRx-001 in Cancer Subjects
|
Phase 1 | |
| Completed |
NCT00725634 -
A Phase 1 Dose-Escalation Study in Advanced Solid Tumors, Lymphomas or Multiple Myeloma
|
Phase 1 | |
| Completed |
NCT01648764 -
A Study of LY2334737 in Participants With Cancer That is Advanced and/or Has Spread
|
Phase 1 | |
| Recruiting |
NCT04083599 -
GEN1042 Safety Trial and Anti-tumor Activity in Subjects With Malignant Solid Tumors
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT02999750 -
EXtendedAnalysis for Cancer Treatment
|
N/A | |
| Completed |
NCT01457118 -
An Extension Study of NKTR-102 in Cancer Patients Previously Enrolled in NKTR-102 Studies
|
Phase 2 | |
| Active, not recruiting |
NCT05539157 -
Study to Evaluate JCXH-211 as Monotherapy in Patients With Malignant Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT04571892 -
A Clinical Study to Observe the Safety and Efficacy of ScTIL210 in the Treatment of Malignant Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05468359 -
Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04168528 -
Phase I/IIa Study of 68GaNOTA-Anti-MMR-VHH2 for PET/CT
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04145622 -
Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06057038 -
A Safety Trial of GEN1042 in Japanese Subjects With Malignant Solid Tumors
|
Phase 1 | |
| Completed |
NCT02844400 -
Cancer Patients' Performance Status Assessed Using Cardiopulmonary Exercise Testing and Wearable Data Generation
|
||
| Completed |
NCT00452413 -
A Study of Enzastaurin and Erlotinib in Participants With Solid Tumors and Lung Cancer
|
Phase 1/Phase 2 | |
| Completed |
NCT03553108 -
A Study Using Olaparib Tablets for Subjects With Advanced Solid Tumours.
|
Phase 1 | |
| Recruiting |
NCT06391775 -
Trial to Assess the Safety and Preliminary Efficacy of GEN1055 on Malignant Solid Tumors as Monotherapy and as Combination Therapy
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04076137 -
Targeted T-cell Therapy in Solid Tumors
|
Early Phase 1 | |
| Terminated |
NCT03192345 -
A First-in-human Study of the Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of SAR439459 Monotherapy and Combination of SAR439459 and Cemiplimab in Patients With Advanced Solid Tumors
|
Phase 1 | |
| Completed |
NCT02754141 -
An Investigational Immuno-therapy Study of Experimental Medication BMS-986179 Given Alone and in Combination With Nivolumab
|
Phase 1/Phase 2 |